"Sinc Preclinical characterization of CYT-100 iPSC derived NK cells alone and in combination with CYT-303 NK cell engager for hepatocellular carcinoma (HCC). Microglial states depend on intrinsic determinants (such as species, ontogeny, sex, or genetic background) as well as the specific context they inhabit, including age, spatial location, and environmental factors (such as nutrition, microbiota, pathogens, drugs, etc.). A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model. Chunxiao Yu, Ph.D.; Kurt Shanebeck; Jieye Sun, Ph.D.; Chao Wang; Shiguang Yu, Ph.D.; Jeannie Luiz; Ray Chuang, Ph.D.; Ming Li, Ph.D.; Yong Wen, Ph.D.; Jeff Lu, Ph.D.; Yuefeng Lu, Ph.D. Cytokine;NK/NKT cell;T cell;Tumor microenvironment, A Single Spark Can Start a Prairie Fire - Re-think the Combination Strategy and Clinical Setting of IL-12 with Anti-PD-1, Pei-Yi Tsou; Wan-Ying Lin; Meng-Na Lee, Ph.D Candidate; San-chi Chen, MD, Checkpoint blockade;Cytokine;Tumor microenvironment, Half-life extended, conditionally active IFNa prodrug induces tumor-selective activation and potent antitumor response, Alice Yam, PhD; Kshama A. Doshi, PhD; Krishna Bajjuri; Millicent Embry; Frank Xiao; Grace Lee; Stephanie Armstrong; Daniel Calarese; Xiaofan Li; Gang Yin; Kristin Bedard, PhD; Trevor Hallam, PhD, Cytokine;Immune toxicity;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment, A safe and highly potent PD-1-IL-2 fusion (AWT020) that decouples the efficacy and toxicity of IL-2 therapy, Fan Ye, Ph.D; Zoey Huang; Jianing Huang; Lili Cheng, Ph.D; Sandra Chen; Danny Huang; Michael Hua; Ella Li; Jenny Jiang; Hanna Lin; Xin Wang; Bella Yue; Shirley Shi; Henry He; Karen Yan; Binfeng Lu, PhD; Ziyang Zhong, Antibody;Checkpoint blockade;Cytokine;NK/NKT cell;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment. Nonetheless, there were a few points that are still under intense debate. Koyama, MD, PhD; Toshio Shimizu; Toshihiko Doi; Noboru Yamamoto; Shunsuke Kondo; Abood Okal, PhD; Aman Singh; Janet Markman; Takenori Akaike; Hideaki Kagehara; Yasutoshi Kuboki, CAR T cells;Clinical trial;Cytokine;Solid tumors;T cell;Tumor microenvironment, Interim dose escalation of davoceticept, a conditional CD28 costimulator and dual checkpoint inhibitor, in combination with pembrolizumab in advanced malignancies (NEON-2), Nehal J. Lakhani, MD; Amita Patnaik; Meredith McKean, MD; Justin F. Gainor, MD; Cathy Vo Buu; Amanda Enstrom; Rupert Davies; Stacey R. Dillon; Hany Zayed; Michael Chisamore; James Michael Pluda; Allison L. Naumovski; Stanford L. Peng, Checkpoint blockade;Clinical trial;Coinhibition;Costimulation;Solid tumors;T cell, A phase 1b/2, open-label, safety, tolerability and efficacy study of NC410 plus pembrolizumab for participants with immune checkpoint inhibitor (ICI) refractory, or MSS/MSI-low ICI naïve advanced or metastatic solid tumors, Han Myint, MD, FRCPath, FRCP; Eric Christenson, MD; Siqing Fu, MD, PhD; Martin Gutierrez, MD; Ashley Martz; Stephanie Zeidan, M.S. New tools for studying microglia in the mouse and human CNS. Brian A. Adang; Tanja D. de Gruijl, PhD; Paul Parren; Benjamin Winograd, MD, PhD; Hans J. Function and Dysfunction of Microglia during Brain Development: Consequences for Synapses and Neural Circuits. Several studies, in both mouse and human stem-cell-differentiated microglia, demonstrated that the transition to a DAM state is dependent on TREM2. Altogether we will prepare a customized course based on the needs and interests of your team. Efficient ex-vivo expansion of adaptive NKG2C+/CD57+ NK cells from CMV-positive donors using dendritic cells derived from the acute myeloid cell line DCOne. Yuqin Y. Target audience: Graduate faculty involved with STEM education. Once abstract titles are listed on the website, press releases can be issued with the titles and logistical information. All classifieds - Veux-Veux-Pas, free classified ads Website. Once abstract titles are listed on the website, press releases can be issued with the titles and logistical information. ; Shukaib Arslan; Hongtao Liu, MD, PhD; Margarida Magalhaes-Silverma, MD; Nelli Bejanyan; Antonio DiStasi; Betul Oran, MD, MS; Jingmei Hsu; Robin McCallum; Silvia Quintero; Gerald M. Garrett; Karrie Wang; Eric A. Smith, PhD; Tsvetelina Hoang, PhD; Tara Shahim; Jeannette Crisostomo; Anna Wilga-Savitski; Jennifer Pickering; Laura Angelo; Anastasiya Smith, PhD, Adoptive immunotherapy;Biomarkers;Clinical study;Clinical trial;Immune monitoring;Leukemia/Lymphoma;T cell;Tumor antigens, Mechanism of action of LAVA-051, a bispecific Vγ9Vδ2 T-cell engager (bsTCE), confirmed in the clinical setting, Roeland Lameris; Jurjen M. Ruben; Rob Roovers; Arnon P. Kater; Thilo Riedl; Victoria Iglesias; Annemiek Broijl; Ilse Tuinhof; Sanjana Umarale; Anton E.P. GCB is an interdisciplinary center where faculty across Dukes campus collaborate to study complex problems in genomic and computational biology, train researchers and develop genomic technologies. Derek Franklin, Ph.D.; Anne Lai, Ph.D.; Faraha Brewer, BSc; Arpita Patel, BSc; Kinsley Evans, BSc; Mahmud Hussain, Ph.D.; Louis Gonzalez, Ph.D.; Keith Wilson, Ph.D.; George J. Fromm, Jr., Ph.D.; Taylor H. Schreiber, MD, PhD; Suresh De Silva, Ph.D. Bispecifics;Costimulation;Cytokine;Leukemia/Lymphoma;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs), Enhancing NK cell function in the 'cold' tumor microenvironment of prostate cancer with a novel Tri-specific Killer Engager against prostate-specific membrane antigen (PSMA), Shee Kwan Phung, BS; Yvette Soignier, PhD; Nicholas A. Zorko, MD, PhD; Trygve Nelson; Joshua S. Walker; Philippa (Pippa) R. Kennedy, PhD; Jeffrey S. Miller, MD; Martin Felices, Bispecifics;Costimulation;Immune suppression;MDSC;Myeloid cells;NK/NKT cell;Targeted therapy;Tumor microenvironment, Selective blockade of CD47-SIRP alpha 'don't eat me' signaling with a Her2-CD47 bispecific antibody-derivative, Yuzhu Qi; Harm J. Lourens; Gerwin Huls; Edwin Bremer, Bispecifics;Monocyte/Macrophage;Targeted therapy, Discovery and preclinical pharmacology of bispecific antibodies targeting an HLA-A2 restricted tumor-associated antigen, Alejandro Ramirez, PhD; Nora Guidotti, PhD; John Leonard, PhD; Olivier Dalmas, PhD; Jake Kleiner; Joshua Goldsmith; Greg Tuffy; Jason Romero; Bindu Hegde, Ph.D.; Tina Giese; Lisa Kirkemo, PhD; Rafaela Truffer; Oralea Buchi; Nadine Uebersax; Philipp Wild, PhD; Rohan Eapen, PhD; Joanna Dreux; Alaina Cagalingan; Lena Flood, PhD; Kyle Pelot, PhD; Nathan Katz; Marvin H. Gee, PhD; Venita De Almeida, PhD; Johannes Schilling, PhD; Patrik Forrer, PhD; Leah V. Sibener, PhD, Bispecifics;Targeted therapy;Tumor antigens, NKp46 engaging Bicycle NK-TICA™ drives targeted tumor cytotoxicity, Alexandra Rezvaya, MS; Fay J. Dufort, PhD; Christopher J. Leitheiser, PhD; Hannah Gardner; Tucker Ezell; Liuhong Chen; Peter Brown; Philip E. Brandish, PhD; Michael Skynner; Kevin McDonnell, PhD; Nicholas Keen, PhD, DuoBody-PD-L1x4-1BB (GEN1046) reverses T-cell exhaustion in vitro, Jordan M. Blum, PhD; Vanessa Spires; Gregg Masters; Christina Yu; Saskia Burm; Matt Hancock; Omar J. Jabado, PhD; Brandon Higgs; Alexander Muik; Kristina Nuermberger; Friederike Gieseke; Tahamtan Ahmadi; Kate Sasser; Ozlem Tureci; Maria Jure-Kunkel; Ugur Sahin; Mark Fereshteh; Nora Pencheva, Antibody;Bispecifics;Checkpoint blockade;Coinhibition;Costimulation;Dendritic cell;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment, Antibody-lectin bispecifics for glyco-immune checkpoint blockade, Jessica C. Stark, PhD; Melissa A. Importantly, we will primarily dedicate speaking opportunities to emerging young investigators as well as people from historically marginalized groups. Join the hormonal regulation Signaling Interest Group Slack channel, Organizers:Nadine Samara, National Institute of Dental and Craniofacial Research, and Stacy Malaker, Yale University. ; Timothy G. Humphries, MD; Sunnie Kim, MD; Adi Diab; Ons Harrabi, BA; Feng Jin, PhD; Hong I. Wan, PhD; Candy Bermingham, PhD; Anthony B. El-Khoueiry, MD, Antibody;B cell;Clinical study;Clinical trial;Solid tumors;TLR;Tumor infiltrating lymphocytes (TILs), A Phase 1/1b dose escalation and cohort expansion study of MGC018 in combination with lorigerlimab in patients with advanced solid tumors (AST), John D. Powderly, II, MD; Patrick Kaminker, PhD; Enxu Zhao, MS; Denise Casey, MD; Eugene Shenderov, MD, PhD, Antibody;Checkpoint blockade;Clinical trial;Coinhibition;Solid tumors;Targeted therapy, A Phase 1 Dose Escalation and Expansion Study of the anti-CD200R1 Antibody 23ME-00610 in Patients with Advanced Solid Malignancies, Drew Rasco, MD; Albiruni R. Razak; Maike Schmidt, PhD; Sariah Kell; Dylan Glatt, PhD; Erin Belshaw; Sophia R. Majeed, PharmD, PhD; Shivaani Kummar, MBBS, Antibody;Checkpoint blockade;Clinical trial;Genetic polymorphism;Solid tumors;T cell, Phase 1b study of LNS8801 in combination with pembrolizumab in patients with secondary resistance to immune checkpoint inhibitors, Jordi Rodon; Marya F. Chaney, PhD; Justine V. Cohen, DO; Tina Garyantes; Jessica J. Lin, MD; Patricia Lorusso, MD; Alain Mita, MD; Monica Mita, MD; Carolyn Muller, MD; Christopher Natale, PhD; Marlana Orloff, MD; Kyriakos P. Papadopoulos, MD; Sapna P. Patel, MD, Biomarkers;Checkpoint blockade;Clinical trial;Genetic polymorphism;Solid tumors;Targeted therapy, A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC T Cells Targeting HER2 in Relapsed or Refractory Solid Tumors, Benjamin L. Schlechter, MD; Daniel Olson, MD; Samuel Saibil, MD; Mridula George, MD; Riemke Bouvier; Jessica McKinley; Brooke Pieke, MS; Jill Geisburger; Nathan J. Ternus, BS; Kara Moss; Deyaa Adib, MD; Ecaterina E. Dumbrava, MD, CAR T cells;Clinical study;Cytokine;Solid tumors;T cell;Targeted therapy, Pharmacokinetic and pharmacodynamic data from a Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients with Advanced Solid Tumors, Randolph Noelle; Melissa L. Johnson, MD; Jordi Rodon; Marjorie Zauderer; Lionel Lewis; Mariano Severgnini; Jefferson Parker; Maureen Lane; Reinhard von Roemeling; Alex S. Martin; Michael Molloy; Robert E. Martell; Tong Dai, Antibody;Biomarkers;Checkpoint blockade;Chemokine;Clinical study;Cytokine;Immune monitoring;Solid tumors, First-in-human Phase 1a study of NG-641, a tumour-selective vector expressing a FAP-TAc bispecific antibody and immune enhancer module, in patients with metastatic/advanced epithelial tumours (STAR), George Simon, MD; Vivek Subbiah; Lee Rosen, MD; Heinz-Josef Lenz, MD; Haeseong Park, MD, MPH; Minesh Patel; David Miles; Stephanie Wallis; Vladimir Evilevitch; David Krige, PhD; Mark Powell; Tom Lillie, Clinical study;Cytokine;Solid tumors;T cell;Tumor microenvironment;Tumor stroma, Phase 1/2 Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies: Initial Results From Dose Escalation, Diwakar Davar, MD; Morteza Aghmesheh, MD, GradDipSc, PhD, FRACP; Alain P. Algazi, MD; David Bajor, MD; Vinod Ganju, MBBS, FRACP; Douglas E. Laux, MD; Alexander I. Spira, MD, PhD, FACP; Elizabeth S. Ahern; Jaspreet S. Grewal, MD, PhD, MPH; Jamie Rand, MD; Randy F. Sweis, MD; Mette Kriegbaum, PhD; Jens-Jakob Karlsson, PhD; Yang Wu, PhD; Tuan-Anh Tran, PhD; Stina M. Singel, MD, PhD; Nashat Y. Gabrail, MD, Clinical study;Clinical trial;Solid tumors;TLR, First-in-human, dose escalation and expansion study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing relapsed/refractory advanced solid tumors: Interim Data. The jury is still out to test whether its full or core signature is common to all or a subset of pathologies, particularly in the human brain. Biomarkers;Clinical study;Clinical trial;Gene expression;Immune monitoring;RNA;Solid tumors;TLR;Tumor microenvironment. For instance, could engrafted parenchymal macrophages functionally replace the resident microglia despite having a different molecular identity, and could they serve as therapeutic vectors? Hughes, MD; Jong Chul Park, MD; Tim Welliver, MD, PhD; Christine Ju; Feng Jin; Alison J. Forgie, PhD; Jaume Pons, PhD; Sophia S. Randolph, MD, PhD; Athanasios C. Tsiatis, MD, Clinical trial;Costimulation;Dendritic cell;Myeloid cells;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs), NT-I7 for the treatment of locally recurrent squamous cell carcinoma of head and neck undergoing salvage surgery: A clinical trial in progress, Hyunseok Kang, MD, MPH; Matthew Spitzer, PhD; Mi-Ok Kim, PhD; Patrick Ha, MD; Daniel Johnson, PhD; Byung Ha Lee, PhD; Se Hwan Yang, PhD, Clinical trial;Cytokine;Tumor infiltrating lymphocytes (TILs), A Phase 1b open-label, single-arm dose expansion study of IK-175, an oral AHR inhibitor, in combination with nivolumab in patients with primary PD-1 inhibitor resistant advanced head and neck cancer, Trupti Lingaraj, B.S. ; Svetlana Bornschlegl, M.S. De novo transcript sequence reconstruction from RNA-seq using the Trinity platform for reference generation and analysis. ; Sally Weng; Ellen Duong, PhD; Sarah Blatt, Checkpoint blockade;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma. ; Kenny Kwok-Hei Yu, MBBS, Ph.D.; Ruby M. Freeman, B.S. OxPhos inhibition offsets the metabolic advantage of pancreatic cancer and promotes a pro-inflammatory tumor microenvironment. ; Pritam Mukherjee, Ph.D.; Heather M. Selby, Ph.D.; Soohee Lee, M.S. Byoung S. Kwon, PhD; Hye Jeong KIM; Joong Won Lee, Antibody;Checkpoint blockade;Monocyte/Macrophage;Tumor microenvironment, YH38560, a novel bispecific fusion protein targeting 5T4 and CD47 in a tumor-selective manner for the treatment of solid cancers, Narae Lee, MS; Eunjeong Jeong; Jung-Hoon Pyun; Minji Choi; Young Bong Park; Yoon ha Hwang; Eunjung Lee; Junhwan Kim; Se-Woong Oh, Bispecifics;Checkpoint blockade;Monocyte/Macrophage;Myeloid cells;NK/NKT cell;Solid tumors;Tumor antigens;Tumor microenvironment, Application of Organoid-based Discovery Platform for Innovative Screening, Evaluation, and Identification (ODISEI) in Immunotherapy, Bo Eun Lee, MS; Sarang Kim; Yuri Shin; Hee-Ra Lee; Suyoung Jo; Dong Wook Han; Jongman Yoo, B cell;Bispecifics;Checkpoint blockade;Dendritic cell;Monocyte/Macrophage;Myeloid cells;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs), Preclinical studies support clinical development of AZD2936, a monovalent bispecific humanized antibody targeting PD-1 and TIGIT, Karin Lee, PhD; Deepali Malhotra, PhD; Stacy Pryts; Eleanor Clancy-Thompson, PhD; Bilal Omar, PhD; Brian Naiman; Michael Overstreet, PhD; Devon K. Taylor; Chunning Yang; Kathy A. Mulgrew; Zhan Xiao; Yue Wang, PhD; Gordon Moody; Mark Cobbold, MD, PhD; Yariv Mazor; Scott A. Hammond, PhD; Kristen N. Pollizzi, PhD, Antibody;Bispecifics;Checkpoint blockade;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs), Botensilimab, an Fc-enhanced CTLA-4 antibody, enhances innate and adaptive immune activation to promote superior anti-tumor immunity in cold and I-O refractory tumors, Chloe Delepine, MEng, MS; Daniel L. Levey, PhD; Shanmugarajan Krishnan, PhD; Kwang-Soo Kim, PhD; Adam Sonabend; Margaret Wilkens; Antoine Tanne, PhD; Pilar Garcia-Brocano; Claire H. Galand, PhD; Haiyong Han, PhD; Christopher MacDermaid; Jacky Chow, PhD, MS; Sylvia Vincent; Shalu Karkwal; Yan Sun; Racehl Smith; Xavier Michelet, PhD; Kah Teong; Katherine Rosenthal, RN, MSN, OCN, CCRP; David Savitsky, PhD; Cailin Joyce, PhD; Steven J. O'Day, MD; Joseph E. Grossman, MD; Jaymin M. Patel, MD; Dhan Chand, PhD, Antibody;Antigen presenting cells;Checkpoint blockade;Clinical study;Costimulation;Dendritic cell;Gene expression;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs), Transient inhibition of cyclin-dependent kinase 4/6 with trilaciclib enhances inhibitory receptor immunotherapy to improve antitumor efficacy, Kun-Hui Lu; Catherine Dietrich; Sarah Ahn; Subing Cao; John S. Yi, PhD; Shom Goel, Checkpoint blockade;Solid tumors;T cell;Tumor microenvironment, Knockdown of VISTA protein using antisense oligonucleotides promotes superior anti-tumor immunity compared to antibody blockade, Brittany A. Morrow, BS; Michael A. Curran, PhD; Priyamvada Jayaprakash, PhD; Alexey Revenko; Patrick Younan, Checkpoint blockade;Granulocyte;Immune suppression;Immune toxicity;MDSC;Monocyte/Macrophage;Myeloid cells;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment, PD-1 blockade administered before or at the time of T cell activation enhances anti-tumor immunity, Jena E. Moseman, BSE; Douglas G. McNeel, MD, PhD, Checkpoint blockade;T cell;Tumor infiltrating lymphocytes (TILs);Vaccine, First-in-class anti-PVR mAb NTX1088 restores expression of DNAM1 and augments antitumor immunity, Akram Obeidat, PhD; Anas Atieh; Alon Vitenshtein; Guy Cinamon, PhD; Keren Paz, PhD; Tihana Rovi; Paola Brilc; Lea Hirsl; Ofer Mandelboim; Stipan Jonjic; Pini Tsukerman, PhD, Antibody;Biomarkers;Checkpoint blockade;Clinical trial;Immune suppression;Myeloid cells;NK/NKT cell;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs), Anti-TIGIT antibody tiragolumab leverages myeloid cells and regulatory T cells to improve PD-L1 checkpoint blockade, Namrata S. Patil, Ph.D.; Raymond Meng, PhD; Robert Johnston; Patrick S. Chang; Shyam Srivats; Yoonha Choi; Xiangnan Guan; Barzin Y. Nabet, PhD; Lisa McGinnis; Eugene Chiang; Thinh Pham; Alexis Dunkle; Bill OGorman; Ira Mellman, PhD; Ruozhen Hu; John Silva; Joy Han; Amelia Au-Yeung; Chikara Takahashi; Nandini Molden; Pallavi Daggumati; Wendy Connolly; Melissa L. Johnson, MD; Delvys Rodriguez Abreu; Byoung Chul Cho, MD, PhD; Antoine Italiano, MD, PhD; Ignacio Gil Bazo; Enriqueta Felip; Sanjeev Mariathasan, PhD; Carlos Bais; David S. Shames, PhD, Checkpoint blockade;Myeloid cells;Regulatory T cell (Treg cell);T cell, LAIR-1 inhibition enhances anti-PD-1 efficacy, Yoshiko Takeuchi, MD PhD; Corazon D. Arthur; Heather N. Kohlmiller; James M. White; Betty Lee; Bin Fan; Jiawei Huang; James Sissons; Jonathan Sitrin; Lee Rivera; Robert D. Schreiber, PhD, Checkpoint blockade;Monocyte/Macrophage;Myeloid cells;Neoantigens;Solid tumors, HBM1047, a novel fully human anti-CD200R1 antagonist antibody with potent anti-tumor efficacy in preclinical model, Yuhua Wang, Ph.D; Qiumei Du; Hongjie Pan; Geetika Bajpai; Tao Liu; Jason Noon; Yao Lu; Jinqiu He; Yan Li; Qingfang Chen; Yongqiang Wang; Xingxing Jia; Fei Chen; Youhong Wang; Yiping Rong; Yun He; Joe Zhao; Musheng Bao, Antibody;Antigen presenting cells;Checkpoint blockade;Coinhibition;Immune suppression;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs), Real-world outcomes in patients with penile squamous cell carcinoma (pSCC) receiving immune checkpoint inhibitors (ICI), Tony Z. Zhuang, MD; Subir Goyal, MBBS, PhD, MSc; Jacqueline T. Brown, MD; Bradley C. Carthon, MD, PhD; Omer Kucuk, MD; Greta R. McClintock, MSN, FNP, DC; Lauren Yantorni, ARNP; Mehmet A. Bilen, MD; Viraj A. To which extent are microglial states plastic and reversible? Combination therapy with anti-VSIG4 and anti-PD-L1 suppress growth of tumor via conditioning of tumor microenvironment. Rachael E. Maynard, MD, PhD Candidate; Allison Fitzgerald; Apsra Nasir; Eric Glasgow, PhD; Sandra Jablonski, PhD; Pieter Van Der Veken; Gray Pearson, PhD; Emily Mace, PhD; Louis M. Weiner, MD, Prognostic value of Natural Killer cell activity and derived neutrophils-to-lymphocytes ratio in non-small cell lung cancer patients receiving immune checkpoint inhibitors, Line Nederby, MSc, PhD; Sara W.C. Wen, MD; Torben S. Hansen, MD; Christa H. Nyhus, MD; Lisbeth Bertelsen, MD; Rikke F. Andersen, MSc, PhD; Anders Jakobsen, MD, DMSc, Professor; Torben F. Hansen, MD, DMSc, Associate Professor, Biomarkers;Checkpoint blockade;Immune suppression;NK/NKT cell;Solid tumors, Complement C3 deficiency increases the anti-tumor immunity of NK cells and controls tumor growth, Girdhari Lal, PhD; PRADIPTA PAL, M.Sc (Integrated Biotechnology); Sourav Paul; Heikrujam Thoihen Meitei; Praneet Wahi; Arvind Sahu, PhD, Cytokine;NK/NKT cell;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment, Natural Killer cells in immunotherapy-induced MHC-I tumor escape, Eric Miao; Jennifer Poursine-Laurent; Kathleen CF. Banks, MD PhD; Smita S. Chandran, PhD; Arianna Correa; Bryan C. Novak; Jessica M. Fleischman; Alexander Drilon, MD; Jedd D. Wolchok, MD PhD; Taha Merghoub, PhD; Christopher A. Klebanoff, MD, Adoptive immunotherapy;Immune monitoring;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs), The Functional Activity of Gavo-cel TRuC-T Cells is not Impaired by Soluble Mesothelin, Michael Lofgren, PhD; Robert Tighe, PhD; Robert Hofmeister, PhD; Jian Ding, PhD; Nate Bagge, BS; Alec Andrews, MS; Michelle Fleury, PhD; Courtney Anderson, PhD, Clinical trial;Solid tumors;T cell;Tumor antigens;Tumor evasion;Tumor microenvironment, Luciferase reporter cancer cell lines facilitate CAR-T development, John G. Foulke, MS; Luping Chen, BS; Brian Della Fera, BS; Hyeyoun Chang, PhD; Kevin Tyo, PhD; Zhizhan Gu, MD, PhD; Fang Tian, PhD, Adoptive immunotherapy;Antigen presenting cells;CAR T cells;Immune monitoring;Leukemia/Lymphoma;Solid tumors;Targeted therapy;Tumor antigens, SENTI-401, an Allogeneic Logic-Gated and Multi-Armed CAR-NK Cell Therapy for the Treatment of CEA-Expressing Solid Tumors with Enhanced Selectivity and Efficacy, Alba Gonzalez Junca, PhD; Nicholas Frankel, PhD; Maelig Morvan, PhD; Assen Roguev, PhD; Michelle Hung, PhD; Russell Gordley, PhD; Miguel R. Palermo; Tyler Santomaso; Pearley Chinta; Aldo Sotelo, MS; Marcus Gainer, MS; Derrick Lee; Tony Hua, PhD; Andrew Banicki; Mengxi Tian; Niran Almudhfar; Atahualpa Contreras; Chen-Ting Lee, PhD; Timothy K. Lu, PhD, Adoptive immunotherapy;Cytokine;NK/NKT cell;Solid tumors;Tumor antigens;Tumor microenvironment, Developing an Adoptive Cell Transfer Immunotherapy for Pediatric High-Grade Gliomas. de Miranda; Loes F.S. ; Marion Subklewe, Prof. Dr. med. ; Tarek Haykal, MD; Michael A. Morse, MD; Alessio Cortellini, MD, PhD; David J. Pinato, MD, MRes, PhD; Alessia Dalla Pria, MD; Mark Bower, MD; Evan T. Hall, MD, MPhil; Veli Bakalov, MD; Nathan Bahary, MD, PhD; Aarthi Rajkumar, MD; Ankit Mangla, MD; Vishal Shah, PharmD, MBA; Parminder Singh, MD; Frank Aboubakar Nana, MD; Nerea Lopetegui Lia, MD; Danai Dima, MD; Pauline Funchain, MD; Rabia Saleem, MD; Rachel Woodford, MD; Georgina V. Long AO, BSc PhD MBBS FRACP FAHMS; Alexander M. Menzies, MD; Carlo Genova, MD, MD; Giulia Barletta, MD, MD; Sonam Puri, MD; Vaia Florou, MD; Dame Idossa, MD; Paola Queirolo, MD; Giuseppe Lamberti, MD; Alfredo Addeo, MD; Melissa Bersanelli, MD, PhD; Dory Freeman, BSc; Wanling Xie, MS; Ramya Ramaswami, MD, MPH; Thomas U. Marron, MD, PhD; Toni K. Choueiri, MD; Kathryn Lurain, MD, MPH; Lindsey R. Baden, MD; Guru P. Sonpavde, MD; Abdul Rafeh Naqash, MD, Checkpoint blockade;Clinical study;Immune suppression;Immune toxicity, Interrogation of immune toxicity in patients with thymic epithelial tumors (TETs), Meredith J. McAdams, MD; Shannon Swift, RN, BSN; Madison Ballman, BA; Abigail Wong-Rolle, BSc; Renee N. Donahue, PhD; Claudia M. Palena, PhD; Jeffrey Schlom, PhD; James L. Gulley, MD, PhD; Arun Rajan, MD; Chen Zhao, MD, Antibody;Autoimmunity;Biomarkers;Checkpoint blockade;Cytokine;Gene expression;Immune toxicity;Solid tumors, Healthcare resource utilization in patients with pre-existing autoimmune diseases who received immune checkpoint inhibitors in the Marketscan database, Jennell Palaia, PharmD, MS; Anna C. Pavlick, MD, MBA; Radhika Pisupati, PharmD; Benjamin C. Fu, PhD, MPH; Keith Wittstock, PharmD, MBA; Ying Zhang, MD, MsPH, Outcomes in patients with pre-existing autoimmune diseases who received immune checkpoint inhibitors: a real-world study, Anna C. Pavlick, MD, MBA; Jennell Palaia, PharmD, MS; Radhika Pisupati, PharmD; Benjamin C. Fu, PhD, MPH; Keith Wittstock, PharmD, MBA; Ying Zhang, MD, MsPH, Checkpoint inhibitor-associated inflammatory arthritis is comprised of multiple clinical endotypes characterized by distinct transcriptional programs, Gary D. Reynolds, MBBS PhD; Mazen Nasrallah, MD; Neal P. Smith; Molly Thomas, MD PhD; Leyre Zubiri, MD; Alice Tirard; John McGuire; Kasidet Manakongtreecheep; Jessica Tantivit; Steven Blum, MD; Daniel A. Zlotoff, MD, PhD; Elaina PuiYee Chan; Dejan Juric, MD; Ryan J. Sullivan, MD; Genevieve M. Boland, MD, PhD; Andrew Luster; Sara Schoenfeld; Minna Kohler; Kerry L. Reynolds, MD; Chloe Villani, PhD, Autoimmunity;Checkpoint blockade;Immune toxicity;Inflammation;T cell, Pre-Treatment Interstitial Abnormalities is a Risk Factor for Immune Checkpoint Inhibitor Pneumonitis in Patients with Lung Cancer, Alexander Wong, MD; Maria Riley, BS; Songzhu Zhao, MS; Jessica Zimmer, BS, BA; Matthew Viveiros, BS; Jing Gennie Wang, MD; Vince Esguerra, MD; Mingjia Li, MD; Gabrielle Lopez, BS; Gregory Otterson, MD; Kari Kendra, MD; Carolyn Presley, MD; Lai Wei, PhD; Dwight H. Owen, MD, MSc; Kevin Ho, MD, Checkpoint blockade;Epidemiology;Immune toxicity;Inflammation;Radiotherapy, TNG260, a CoREST-selective deacetylase inhibitor, reverses anti-PD1 resistance driven by loss of STK11, Leanne G. Ahronian, PhD; Xinyuan Wu; Minjie Zhang; Chengyin Min; Alice W. Tsai; Jacques Ermolieff; Patrick McCarren; Margaret Wyman; Ye Wang; Alborz Bejnood; Kenjie Amemiya; Brian McMillan; Nikitha Das; Brian Doyon; Andre Mignault; Colin Liang; Vassil Elitzin; Yi Yu, PhD; Samuel Meier; Ashley Choi; John P. Maxwell; Alan Huang, PhD, Checkpoint blockade;Epigenetics;MDSC;Regulatory T cell (Treg cell);T cell;Targeted therapy, Treatment patterns and immunotherapy rechallenge in advanced or metastatic upper gastrointestinal cancer in a US real-world setting, Jaffer A. Ajani, MD; Marley Boyd; Jenifer Wogen; Ilia Ferrusi; Peyman Nakhaei; Lakshmi Menon-Singh; Ailis Fagan, Checkpoint blockade;Chemotherapy;Clinical study;Immune suppression;Solid tumors;T cell;Tumor microenvironment, HR+ breast cancer: Defining innate and acquired resistance to immune checkpoint inhibitors, Aitziber Buqu Martinez, PhD; Norma Bloy, PhD; Michal Hensler, PhD; Giulia Petroni, PhD; Ai Sato, MSc; Takahiro Yamazaki, PhD; Bhavneet Bhinder, MS; Jitka Fucikova; Olivier Elemento, PhD; Silvia C. Formenti, MD; Lorenzo Galluzzi, PhD, Carcinogenesis;Immune adjuvant;Immune suppression;Immune tolerance;Tumor microenvironment, Dual targeting of PD-1 and CTLA-4 synergizes with focal radiation to durably increase survival against glioblastoma, Mara De Martino, PhD; Camille Daviaud; Claire I. Vanpouille-Box, PhD, Checkpoint blockade;Immune suppression;Radiotherapy;Solid tumors;T cell;Tumor microenvironment, Driver mutation analysis as a selective marker for immunotherapy in patients with pheochromocytoma and paraganglioma, Katerina Hadrava Vanova, PhD; Ondrej Uher, PhD; Leah Meuter; Suman Ghosal, PhD; Jiri Neuzil, PhD; Karel Pacak, MD, PhD, Checkpoint blockade;Gene expression;Genetic polymorphism;Immune monitoring;Solid tumors;Targeted therapy;Tumor microenvironment, Cyclic disruption of the mitogen-activated protein kinase (MAPK) pathway by the dual MEK inhibitor, IMM-6-415, enhances PD1 and CTLA4 checkpoint blockade in RAS mutant tumors, Brett Hall, Ph.D.; Anna Travesa, Ph.D.; Amy Yamamura; Amy Axel; Sarah Kolitz, PhD; Jason Funt, Ph.D.; Kevin Fowler, Ph.D.; Matthew Nord, Ph.D.; Praveen Nair, Ph.D.; Scott Barrett, M.D. How many different microglial states can be identified? The key upregulated (red) and downregulated (blue) genes in each signature are indicated. White matter aging drives microglial diversity. Aideen E. Ryan, PhD; Oliver Treacy, PhD; Kevin Lynch, PhD; Kim De Veirman; Karin Vanderkerken; Laurence J. Egan, Prof; Thomas Ritter, Prof; Aisling M. Hogan; Keara Redmond; Sean Hynes; Emma M. Kerr, PhD; Michael O'Dwyer; Philip D. Dunne; Niamh A. Leonard, MSc; Hannah Egan, BSc, Checkpoint blockade;Glycoproteomics;Immune suppression;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma, AIM2 modulates azacytidine-induced antitumor immunity in lung cancer, Naoki Furuya, MD, PhD; Sumei Lu, PhD; Tamio Okimoto, MD, PhD; Yi Wang; No Joon Song; Anqi Li, MD; Hong Dong, PhD; Bao Zhao; Ju Hwan Cho, PhD; David P. Carbone, MD, PhD; Zihai Li, MD, PhD; Haitao Wen; Kai He, MD, PhD, Biomarkers;Epigenetics;Inflammation;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment, Multiplexed ion beam imaging identifies B-cell enrichment in the RHAMM-high invasive niche of breast cancer, Yuyu He, MD, MS; Grant M. Barthel; Raghav Padmanabhan; Colleen Forster; Hanna Root; Mate L. Nagy, PhD; Stanislaw Nowak, PhD; James B. McCarthy; Kathryn L. Schwertfeger; Andrew C. Nelson, B cell;Biomarkers;Monocyte/Macrophage;T cell;Tumor microenvironment;Tumor stroma. Trinity combines three independent software modules: Inchworm, Chrysalis, and Butterfly, applied sequentially to process large volumes of RNA-seq reads. Join the Chemical Biology Interest Group Slack channel, Organizers: Marina Holz, New York Medical College, andMythreye Karthikeyan, University of Alabama, Birmingham. A population of ectoenzyme expressing T-cells with an immunosuppressive phenotype are associated with checkpoint immunotherapy resistance in metastatic melanoma patients. Dictys: dynamic gene regulatory network dissects developmental continuum with single-cell multi-omics, Single-cell normalization and association testing unifying CRISPR screen and gene co-expression analyses with Normalisr, SCENIC: single-cell regulatory network inference and clustering, Inferring gene regulatory networks from time-stamped single cell transcriptional expression profiles, A Scanpy extension for analyzing single-cell T-cell receptor (TCR) sequencing data, Multiset multicover methods for discriminative marker selection, SCMarker: ab initio marker selection for single cell transcriptome profiling. Innate immune memory in the brain shapes neurological disease hallmarks. RNA-seq Analysis Workshop Course Materials. Anastasios Dimou, MD; Vera Suman; Kristina Denic; Lisa Kottschade; Heather Montane; Heidi D. Finnes; Kristina Franta; Jill Schimke; Yiyi Yan; Robert McWilliams; Matthew Block; James Jakub; Joel Reid; Svetomir N. Markovic, MD, PhD, Intratumorally administered CV8102 in patients with advanced solid tumors: Preliminary results from ongoing expansion part in study 008. Linnaeus and the Linnaeans: The Spreading of their Ideas in Systematic Botany, 1735-1789. Trinity references: Full-length transcriptome assembly from RNA-Seq data without a reference genome. Alexa R. Heaton, PhD; Anna Hoefges, MS; Peter R. Rehani, BS; Nathaniel J. Burkard; Arika S. Feils, BS; Dan V. Spiegelman, BS; Noah W. Tsarovsky, BS; Alina Hampton; Amy K. Erbe, PhD; Alexander L. Rakhmilevich, MD, PhD; Paul M. Sondel, MD, PhD; Melissa C. Skala, Ph.D. Antibody;Checkpoint blockade;Immune contexture;Metabolism;Radiotherapy;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine, Delta-radiomics predicts response and overall survival in advanced non-small cell lung cancer patients treated with durvalumab, Mohammadhadi Khorrami, PhD; Vidya Sankar Viswanathan, M.B.B.S. ; Marissa Timothy, MS; Nerymar Ortiz-Otero; Wilmin Bartolini; Katherine Kacena; Karim Malek; Sergio L. Santillana, MD, MSc, MBA, A phase 1 study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer, Christine H. Chung, MD; Dimitrios Colevas, MD; Douglas R. Adkins; Jong Chul Park, MD; Cristina P. Rodriguez, MD; Michael K. Gibson, MD PhD; Ammar Sukari, MD; Barbara A. Burtness, MD; Faye M. Johnson, MD, PhD; Ricklie A. Julian, MD; Nabil F. Saba, MD; Lara A. Dunn, MD; Tanguy Y. Seiwert, MD; Francis P. Worden; Rami Y. Haddad, MD; Nashat Y. Gabrail, MD; Julie E. Bauman, MD, MPH; Laura Agensky; Apollina Goel, PhD; Reena Lynam; Steven P. Margossian, MD, PhD; Raymond J. Moniz, PhD; Steve N. Quayle, PhD; Cynthia Rajan; Kenneth J. Pienta, MD; Matteo Levisetti; Sara I. Pai, MD PhD, Checkpoint blockade;Clinical study;Clinical trial;Cytokine;T cell;Targeted therapy;Tumor microenvironment, Changing the Radiation and Immune-Oncology Paradigm with the Radioenhancer NBTXR3: Overcoming resistance to anti-PD-1 blockade from the bench to the clinic, Ari Rosenberg, MD; Jessica Frakes, MD; Jiaxin Niu; Jared Weiss, MD; Jimmy Caudell; Patricia Said; Pavel Tyan; Sebastien Paris; Tanguy Y. Seiwert, MD; Colette Shen; Sergio Szyldergemajn; Omar Vivar, PhD; Leonard A. Farber, MD, Checkpoint blockade;Clinical trial;Radiotherapy;Solid tumors;T cell, CD8 T cell repertoire analysis of patients with resectable head and neck cancer enrolled in a phase II neoadjuvant study of -PD1 administered alone or in combination with -CTLA4 or -LAG3, Patricia M. Santos, PhD; Aditi Kulkarni; Housaiyin Li; Jie Chen; Lazar Vujanovic, PhD; Seungwon Kim; Umamaheswar Duvvuri; Dan P. Zandberg, MD; Robert L. Ferris, MD, PhD, Checkpoint blockade;Clinical trial;Immune suppression;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment, NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with advanced cancers: results from an ongoing dose escalation Phase I trial (Study 1100), Colette Shen; Jessica Frakes, MD; Jiaxin Niu; Jared Weiss, MD; Jimmy Caudell; Tanguy Y. Seiwert, MD; Patricia Said; Mickael Guedj; Pavel Tyan; Omar Vivar, PhD; Sergio Szyldergemajn; Leonard A. Farber, MD; Ari Rosenberg, MD, Preliminary Results of MT-401 in Post-Transplant MRD+ AML Patients, Mythili Koneru, MD, PhD; Juan Vera, M.D. 8 , 14941512 (2013). All sessions and events will take place at the Pennsylvania Convention Center unless otherwise noted. Attendees will also be asked to identify and/or anticipate any advantages or disadvantages to changing to a new teaching modality, such as increased/decreased student engagement. come from the School of Medicine, Pratt School of Engineering, Nicholas School of the Environment, and the Trinity College of Arts and Sciences; apply modeling and experimentation to understand and design complex biological systems using a Bispecific antibodies that block TIM-3 and CD39 induce anti-tumor efficacy and immune response by blocking multiple suppressive mechanisms. Such a mission establishes a key common ground between the ASBMB and the chemical biology communitygiven complementary strength and interest. Prediction of HCC response to neoadjuvant immunotherapy using multiparametric magnetic resonance imaging: a preliminary study. Neoadjuvant Vidutolimod (Vidu) and Nivolumab (Nivo) Results in MPR and Immune Activation in High-Risk Resectable Melanoma (MEL): Final Phase II Clinical Trial Results. S.C. is a recipient of research funding from Eli Lilly and Company. MATCHER takes multiple types of single cell measurements performed on distinct single cells and infers single cell multi-omic profiles. As resident macrophages of the brain parenchyma, microglia participate in many critical CNS functions ranging from glio-, vasculo-, and neurogenesis to synaptic and myelination through their process motility, release of soluble factors, and capacity for phagocytosis (. This continuous microglial sensing results in multiple transcriptional signatures from development to aging depending on the specific local signals or challenges to the brain at each developmental stage. A. Sierra is a recipient of a research grant from Hoffmann La Roche. Preclinical Characterization of D3L-001, a novel bispecific antibody that enhance phagocytosis and eradication of HER2 positive solid tumor via HER2 and CD47 dual blockade. How to determine whether and when two or more molecules bind to each other in vivo. Network analysis of transcriptomic diversity amongst resident tissue macrophages and dendritic cells in the mouse mononuclear phagocyte system. This work was supported by grants from the Dementia Research Switzerland Synapsis Foundation , Swiss National Science Foundation ( SNSF 310030_197940 ), and European Research Council ( ERC StGrant REMIND 804949 ) to R.C.P. Alex Allen, Ph.D.; Kaitlyn M. Izzo; Mrunali Jagdale; Scott Mordecai; Jared Getgano; Laura Blaha; Abhijit Dandapat; Mark S. Shearman; Kai-Hsin Chang, Ph.D. Adoptive immunotherapy;NK/NKT cell;Solid tumors, Cell therapy development in oncology requires a collaboration between sponsors and cell therapy experienced CROs, Adoptive immunotherapy;CAR T cells;Cytokine;NK/NKT cell;T cell;Tumor infiltrating lymphocytes (TILs), Characterization of CT-0508, an anti-HER2 chimeric antigen receptor macrophage (CAR-M), manufactured from patients enrolled in the phase 1, first in human, clinical trial of CT-0508, Michael Ball, PhD; Madison Kremp; Rehman Qureshi; Poonam Sonawane, Ph.D.; Maggie Schmierer; Josh VanDuzer; Michael Lynch; Adam Pfendt; Melissa Christiano; Ken Locke; Ramona Swaby; Daniel Cushing, PhD; Michael Klichinsky, PharmD, PhD; Thomas Condamine, PhD, Adoptive immunotherapy;Antigen presenting cells;Biomarkers;Monocyte/Macrophage;Myeloid cells;Solid tumors, Next generation CAR-T incorporating an inhibitory CAR (iCAR) for increased safety in solid tumors, David Bassan, PhD; Michael R. Weist; Leehee Weinberger; Jason Yi; Gregor Adams; Tanya Kim; Caitlin Schnair; Kristina Vucci; Sarit Tabak; Neta Chaim; Nir Bujanover; Yael Lopesco; Limor Levy-Kanfo; Orit Foord; Jim Johnston; Frank Calzone; Rick Kendell; Adi Sharbi-Yunger, ALK chimeric antigen receptor T cells cooperate with ALK inhibitors to target neuroblastoma cells with low target density, Elisa Bergaggio, Ph.D.; Wei-Tien Tai; Andrea Aroldi; Elisa Landoni; Manuel Nuesch; Ines Mota; Jasna Metovic; Leyuan Ma; Diego Alvarado, Ph.D.; Chiara Ambrogio; Claudia Voena; Rafael B. Blasco; Tongqing Li; Daryl Klein; Darrell J. Irvine, Ph.D.; Mauro Papotti; Barbara Savoldo; Gianpietro Dotti; Roberto Chiarle, CAR T cells;Pediatric tumors;Solid tumors;Targeted therapy, Pre-clinical development of a CAR Monocyte platform for cancer immunotherapy, Linara Gabitova, PhD; Brett Menchel, MBT; Silvia Beghi, PhD; Larissa Ishikawa, PhD; Rehman Qureshi; Andrew Best, MA; Sabrina DeLong, PhD; Sascha Abramson, PhD; Thomas Condamine, PhD; Daniel Blumenthal, PhD; Michael Klichinsky, PharmD, PhD, Adoptive immunotherapy;Antigen presenting cells;Monocyte/Macrophage;Myeloid cells;Solid tumors, Immunometabolic Modulation of Engineered iPSC-NK Cells for Immunotherapy of Solid Tumors. Sheehan; Robert D. Schreiber, PhD; Wayne M. Yokoyama; Sytse J. Piersma, PhD, Checkpoint blockade;Immune suppression;Neoantigens;NK/NKT cell;Solid tumors;Targeted therapy;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment, IL-2 expanded tumor infiltrated Natural Killer (TINK) cells from canine sarcomas possess potent anti-tumor cytotoxicity, Weiqing Jing, PhD; Himaly Shinglot; Juliana Chi Kei Ng; Ali Zhang; Bernard Seguin; Jeffrey Bryan; Timothy Fan; Jennifer D. Wu, PhD; Seth M. Pollack, NK/NKT cell;Solid tumors;Tumor infiltrating lymphocytes (TILs), A tumor model in the humanized immuno-reconstituted hIL15 transgenic mice revealed the impact of other immune components on the development and function of NK cells against malignancies, Li Yang; Chunlei Dai; Hongmei Xu; Hui Qi; Xuzhen Tang; Qingyang Gu; Qunsheng Ji, PhD, Immune suppression;NK/NKT cell;Regulatory T cell (Treg cell);Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment, Multifunctional Natural Killer Cell Engager Releasing CXCL10 Augments Natural Killer Cell Recruitment and Anti-tumor Efficacy against Glioblastoma, Antibody;Bispecifics;Chemokine;Cytokine;NK/NKT cell;Solid tumors;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment, CSF1R+PD-L1+ Tumor-associated Macrophages Trigger MAIT Cell Dysfunction at the HCC Invasive Margin, Benjamin Ruf, M.D. Specification of CNS macrophage subsets occurs postnatally in defined niches. Quantifying the Waddington landscape and biological paths for development and differentiation. TAM receptors regulate multiple features of microglial physiology. ; Samuel Theuerkauf, MSc. Tumor microenvironment immune cell landscape varies among molecular subtypes in gastric cancer. The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. And yet, we humans instinctively tend to name things and use that name to define their properties. This work was also funded by DFG CRC/TRR167 NeuroMac to I.A., J.P., M.P., and S.J. Duncan M. Morgan, Ph.D.; Vidit Bhandarkar, BS; Emi Lutz; K. D. Wittrup; Stefani Spranger, PhD; Teresa Dinter, BS, Checkpoint blockade;Costimulation;Cytokine;T cell;T cell lineages, Illuminating stem memory T cell (Tscm) heterogeneity in human cancer: Characterization of a unique CD45RO+ Tscm population in human ovarian cancer, Erica G. Brown, BS; Monika Eiva; Veethika Pandey; Alexander Benton, BA; Stacy K. Thomas; Wenzhao Meng; Aaron M. Rosenfeld; Eline T. Luning Prak; Daniel J. Powell, Jr., PhD, Stem cell/cancer-initiating cell;T cell;Tumor infiltrating lymphocytes (TILs), Single Cell Evaluation of Costimulatory and Coinhibitory Receptors and Their Ligands Across Solid Tumor Indications, Shawn P. Fahl, PhD; Kerri Colwell; Cavin Ott; Casey Smith; Kayla Williams; Alex Moore, Coinhibition;Costimulation;Myeloid cells;NK/NKT cell;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma, Chronic antigen in solid tumors drives a distinct program of T cell residence, Noah V. Gavil, BA; Milcah Scott, BS; Eyob Weyu; Olivia Smith; Stephen D. O'Flanagan; Sathi Wijeyesinghe, MD, PhD; Sahar Lotfi-Emran, MD, PhD; Stephen L. Shiao, MD, PhD; Vaiva Vezys, PhD; David Masopust, PhD, Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment, IL-12 and IL-27 upregulate CD39 expression on CD8+ T-cells and differentially affect CD39+CD8+ T-cell effector function, Lara Gerhardt, BSc; Rene Figueredo, MSc; Saman Maleki, PhD, Cytokine;T cell;Tumor infiltrating lymphocytes (TILs), Engineering of T cells with CCR10 for enhanced trafficking of adoptive cell therapy, Jong Moo Hong; Hee Jin Lee; Gyung Yub Gong; Kwang Hee Kim, PhD, PSGL-1-deficiency suppresses tumor growth of orthotopic pancreatic ductal adenocarcinoma tumors and enhances immune cell infiltration and CD8+ T cell responses, Jennifer L. Hope, PhD; Yijuan Zhang, PhD; Ashley B. Palete; Hannah A. Faso; Sreeja Roy, PhD; Dennis C. Otero, PhD; Swetha Maganti; Cosimo Commisso, PhD; Linda M. Bradley, PhD, Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs), Acetyl CoA Carboxylase Inhibition Rewires T cell Fate and Tumor Immunotherapy Outcome, Katie Hurst; Brian P. Riesenberg, PhD; Elizabeth Hunt, BS; Alex M. Andrews, PhD; Megan Tennant, MS; Evelyn Gandy; Peng Gao; Lauren Ball, PhD; Emily Wallace; David Corcoran; Jessica E. Thaxton, PhD, MS, Metabolism;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment, Uncoupling CD39 and T cell antigen specificity in brain tumors, Jordan F. Isaacs; Sierra A. Kleist; Shawn C. Musial; Hanna N. Degefu; Pamela C. Rosato, PhD, Immune suppression;Inflammation;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine, Stem-like CD8 T-cells residing in antigen presenting immune niches are prognostic for local control in brain metastases and are sustained following radiation therapy, Caroline S. Jansen, PhD; Prasanthi Chappa; Nataliya Prokhnevska, BS; Maria Cardenas; Roshan Prabhu; Jim Zhong; Kimberly B. Hoang; Subir Goyal, MBBS, PhD, MSc; Suzanna Logan; Jeffrey Olson; Edjah K. Nduom, MD; Luke del Balzo; Kirtesh R. Patel, MD; Stuart Burri; Anthony Asher; Scott Wilkinson, PhD; Ross Lake; Kristin Higgins; Pretesh Patel; Vishal Dhere; Mylin Torres; Adam G. Sowalsky, PhD; Mohammad K. Khan; Haydn Kissick, PhD; Zachary Buchwald, MD PhD, Antigen presenting cells;Biomarkers;Dendritic cell;Immune contexture;Immunoscore;Radiotherapy;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment, Analysis of factors associated less differentiated T cells in breast cancer for improvement of adoptive T cell therapy, Sung Wook Jung; Jeong-Han Seo, PhD candidate; Hyeonjin Lee; Gyungyub Gong; Hee Jin Lee, High-dimensional Immune Profiling of Peripheral Epstein-Barr Virus-specific T cells in Nasopharyngeal Carcinoma, Nandita Kumar, BS; Hugh R. MacMillan, PhD; Joe Poh Sheng P. Yeong, MD, PhD; Melvin L. Chua, MBBS, FRCR, PhD, FAMS; Amit Jain, MBBS, MRCP, MMed; Evan W. Newell, PhD, Antigen presenting cells;Biomarkers;Immune monitoring;T cell;Tumor antigens, Ron kinase as potential immunotherapeutic target for augmenting T cell activity in breast cancer metastasis, Immune suppression;T cell;T cell lineages;Tumor evasion;Tumor infiltrating lymphocytes (TILs), Single cell evaluation of antigen specificity, clonal dynamics and transcriptional signatures of CD8+ T cells in Head and Neck Squamous Carcinoma, Housaiyin Li; Patricia M. Santos, PhD; Aditi Kulkarni; Alok V. Joglekar, PhD; Lazar Vujanovic, PhD; Robert L. Ferris, MD, PhD, Checkpoint blockade;Neoantigens;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment, Loss of PD-1 signals improves CD8+ TIL function in a cell intrinsic and cell extrinsic manner, Samuel C. Markson, PhD; Kristen E. Pauken; Vikram Juneja; Osmaan Shahid; Kelly P. Burke; Jared Rowe; Jacklyn Long; Megan Fung; Jacob M. Luber; Jennifer Judge; Alison Ringel; Marcia C. Haigis, PhD; Meromit Singer; Arlene H. Sharpe, Bioinformatics;Checkpoint blockade;T cell. ; Dave Delano; Charles W. Abbott, PhD; Robin Li, MS; Zeid Rusan; John S. West, MBA; John Lyle; Sean M. Boyle, PhD, MS; Richard O. Chen, MD, B cell;Gene expression;Granulocyte;Immune contexture;T cell;Tumor infiltrating lymphocytes (TILs), Comprehensive in situ immune phenotyping with the CosMxTM high plex protein assay, Tien M. Phan-Everson, PhD; Jianji Chen, PhD; Zachary Lewis, PhD; Gary Geiss, PhD; Yan Liang, MD PhD; Emily Brown; Liuliu Pan, PhD; Stefan Phelan, MS; Charlie Glaser; Mithra Korukonda, PhD; Carl Brown, PhD; Dwayne Dunaway, PhD; Joseph Phan, PhD; Alyssa Rosenbloom, PhD; Brian Filanoski, PhD; Rhonda Meredith; Kan Chantranuvatana; Brian Birditt; Giang Ong, MS; Hye Son Yi; Erin Piazza, PhD; Jason W. Reeves, PhD; Subham Basu, PhD; Christine Kang, PhD; Vik Devgan, PhD; Edward Zhao, PhD; Michael Rhodes, PhD; Joseph M. Beechem, PhD, Antibody;B cell;Biomarkers;Monocyte/Macrophage;NK/NKT cell;Regulatory T cell (Treg cell);T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma, TAP2 deficiency mediates adaptive immune evasion and immunotherapy resistance in human non-small cell lung cancer, Kishu Ranjan, Ph.D.; Imad Ud Deen, MD; Miguel Lpez de Rodas, MD; Nicole Gianino, MS; Soldano Ferrone, MD, PhD; Kurt A. Schalper, MD, PhD, Biomarkers;Checkpoint blockade;Chemokine;Cytokine;Gene expression;Solid tumors;T cell;Tumor antigens;Tumor evasion;Tumor microenvironment, Complementary PhenoCode Signature Panels comprehensively map cell interactions and identify Spatial Phenotypic Signatures in the tumor microenvironment, Bethany Remeniuk; Bei Hopkins, MS; Natalie Monteiro; Darren Locke, Biomarkers;Checkpoint blockade;Immune contexture;Immune suppression;Inflammation;Myeloid cells;Solid tumors;T cell;Tumor microenvironment;Tumor stroma, Circulatory plasma proteomic biomarkers predict response to immunotherapy in melanoma patients and reveal biological insights into the tumor microenvironment, Arnav Mehta; Marijana Rucevic; Emmett Sprecher; Nir Hacohen; Genevieve Boland, MD PhD; Milan Parikh; Jiajia Chen; Dennie T. Frederick; Elliot Woods; Lynn Bi; David Lieb; Lina Hultin-Rosenberg; Jamey Guess; Ryan J. Trinity: RNA-Seq De novo Assembly Application. Gallagher; Charlotte Graham; Caron A. Jacobson, MD, MMSc; Rhine Shen; Simone Filosto, PhD; Justin Budka; Sao-Mai Nyugen-Mau; Jenny Nater; Mike Mattie, PhD; Gad Getz; Nicholas J. Haradhvala; Marcela V. Maus, MD, PhD, Bioinformatics;CAR T cells;Chemokine;Clinical trial;Gene expression;Immune toxicity;Inflammation;Monocyte/Macrophage;Regulatory T cell (Treg cell);T cell, Allogenic adoptive NK cells and irradiation join force to control triple negative breast cancer stem cells, Adoptive immunotherapy;NK/NKT cell;Radiotherapy, Targeting Ewing sarcoma with anti-IL1RAP chimeric antigen receptor modified natural killer cells, Wen Luo, PhD; Poul Sorensen, PhD; Mitchell S. Cairo; Hai Hoang; Yaya Chu, PhD; Janet Ayello, MS, MT(ASCP); Wei Li, PhD; Michael Lizardo, PhD; Renata Ribeiro; Melanie Rouleau; Dimiter S. Dimitrov, PhD; Dean A. Lee; Hai-Feng Zhang, PhD, NK/NKT cell;Pediatric tumors;Solid tumors, Off-the-shelf iPSC-derived CAR-T cells containing seven functional edits overcome antigen heterogeneity, improve trafficking, and withstand immunosuppression associated with failed tumor treatment, Martin Hosking, PhD; Soheila Shirinbak, PhD; Bishwas Shrestha, PhD; Joy Grant; Kyla Omilusik, PhD; Hannah Keegan; Demetrio Cardenas; Angela Gentile; Shilpi Chandra, PhD; Lorraine Loter; Lexe Linderhof; Nicholas Brookhouser, PhD; Stephanie Kennedy; Francisco Martinez, PhD; Loraine Campanati; Chris Ecker, PhD; Xu Yuan, PhD; Karina Palomares, PhD; Yi-Shin Lai, PhD; Lauren Fong, PhD; Yijia Pan, PhD; Shohreh Sikaroodi, PhD; Mark Jelcic, PhD; Philip Chu; Amit Mehta, PhD; Layton H. Smith, PhD; Eigen Peralta, PhD; Tom T. Lee, PhD; Ramzey Abujarour, PhD; Raedun Clarke, PhD; Bob Valamehr, PhD, Adoptive immunotherapy;CAR T cells;Chemokine;Immune suppression;Solid tumors;T cell;Tumor evasion;Tumor microenvironment, Combination immunotherapy using a novel chimeric oncolytic virus to redirect CD19 bispecific T cell engagers to target solid tumors, Anthony K. Park, PhD; Saul J. Priceman, PhD; Leslie M.O. MerTK Is a Functional Regulator of Myelin Phagocytosis by Human Myeloid Cells. Herein, we summarize our current knowledge about the identity of microglia and discuss best practices for how to define and study microglial state dynamics. Visualization of microglia in living tissues using Iba1-EGFP transgenic mice. Schedule for the single-cell RNA-seq data analysis workshop Pre-reading Introduction to scRNA-seq Raw data to count matrix Download this project Day 1 Before the next class: I. The 2022 ASBMB Annual Meeting, held in conjunction with Experimental Biology, will take place in person April 25 in Philadelphia. Thus, the term homeostatic should always be accompanied by an accurate description of the context. Master, MD, PhD; Haydn Kissick, PhD; Mehmet A. Bilen, MD; Zachary Buchwald, MD PhD; David C. Qian, MD, PhD, NT-I7, a novel long-acting interleukin-7, improves engraftment of patient immune cells and efficacy of anti-PD-1 therapy in a preclinical humanized melanoma model, Yee Peng Phoon, PhD; Kang Kai, PhD; Alexandra A. Wolfarth, PhD; Sara Ferrando-Martinez, PhD; Byung Ha Lee, PhD; Brian Gastman, MD, Adoptive immunotherapy;Checkpoint blockade;Immune adjuvant;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment, Interim results for Phase 1b dose expansion of MTL-CEBPA in combination with pembrolizumab in patients with advanced solid tumour malignancies, Ruth Plummer; Mikael H. Sodergren, MD, PhD; Brid Ryan; Ilian Tachkov; Vikash Reebye; Tim Meyer; David J. Pinato, MD, MRes, PhD; Debashis Sarker; Bristi Basu; Sarah P. Blagden; Natalie Cook; Jeff Evans; Jeffrey Yachnin; Cheng-Ean Chee; Daneng Li, MD; Anthony B. El-Khoueiry, MD; Maria Diab; Kai-Wen Huang; Antonio D'Alessio; Claudia A.M. Fulgenzi; Marcus Noel; Bridget P. Keenan, MD, PhD; Devalingam Mahalingam, MBBChBAO; Nina Raulf; Rose Hogson; Choon Ping Tan; Joanna Nicholls; Alison Adderkin; Julia Vassiliadou; Robert Habib; John Rossi; Nagy Habib, Checkpoint blockade;Clinical study;Immunoscore;MDSC;Monocyte/Macrophage;T cell;Tumor microenvironment. Conceptual framework and recommendations on microglial nomenclature are provided, serving as foundations for a future white paper. Ultrastructural characterization of dark microglia during aging in a mouse model of Alzheimer's disease pathology and in human post-mortem brain samples. Vaishali Aggarwal, PhD; Chang Liu, PhD; Lawrence P. Andrews, PhD; Madhu Malinee; Carly Cardello; Creg Workman, PhD; Dario A. Vignali, PhD, Checkpoint blockade;Cytokine;T cell;T cell lineages;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment, Treatment with SQ3370, a doxorubicin-based therapeutic, corresponds with immunomodulation of the tumor microenvironment, Masa Aleckovic, PhD; Sangeetha Srinivasan, PhD; Jesse M. McFarland, PhD; Leslie Priddy, B.S; Matthew Tso, MS; Jose M. Mejia Oneto, MD, PhD, Chemotherapy;Clinical trial;Dendritic cell;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma, SQ2270, a Novel MMAE-based Therapeutic, Promotes Tumor Growth Inhibition and Extensive Immune Cell Infiltration in the RENCA Cancer Model, Masa Aleckovic, PhD; Sangeetha Srinivasan, PhD; Jesse M. McFarland, PhD; Leslie Priddy, B.S; Matthew Tso, MS; George Coricor, PhD; Jose M. Mejia Oneto, MD, PhD, T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma. ; Artem Poltoratskiy, MD; Marina Sekacheva, MD; Yuliya Semiletova, MD; Janina Henze, Dr.; Beate Schmitt-Bormann, Dr.; Paula L. Cod, Dr.Sc.Nat. All our training content is as per industrial requirement and 100% practical exposure which will help candidate to make their better career in the field of bioinformatics. This session will feature recent work in the field examining pathways and molecules that cause neurological dysfunction, with a particular emphasis on genetic neurodevelopmental disorders. med. Characterization of the microglial phenotype under specific pro-inflammatory and anti-inflammatory conditions: Effects of oligomeric and fibrillar amyloid-beta. ; Viviane Tabar, M.D. El tercer elemento de los centros nerviosos. ; Paul M. Sondel, MD, PhD; Zachary S. Morris, MD, PhD; Jens Eickhoff, PhD; Michael A. Newton, PhD; Irene M. Ong, PhD; Rene Welch Schwartz, PhD; Rubi Hayim, BS; Sarah Adrianowycz, DVM; Rachel Uyehara, DVM; Ilene D. Kurzman, PhD; Michelle Turek, DVM; David M. Vail, DVM, Checkpoint blockade;Immune monitoring;Radiotherapy;Solid tumors;T cell;Vaccine, Potentiating radiotherapy-induced abscopal immunity by ATR abrogation and CTLA-4 blockade in colorectal cancer, Rodney Cheng-En Hsieh, MD, PhD; Ricardo Alexandre De Azevedo; Pham Hong Anh Cao; Arthur J. Liu, BS; Akash R. Boda, MS; Michelle Winkler, BS; Broderick Turner; Michael A. Curran, PhD, Antigen presenting cells;Checkpoint blockade;Solid tumors;Tumor antigens;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment, Deciphering of radiotherapy-induced immunomodulation effect synergized with immunotherapy in hepatocellular carcinoma by spatial multi-omics profiling, Mai Chan Lau; Lisda Suteja; Lawrence Cheung; Jeffrey C. Lim; Chun Jye Lim; Xinru Lim; Neslihan A. Kaya; Jiang Feng Ye; Felicia Wee; Han Chong Toh; Su Pin Choo; Suat Ying Lee; Joycelyn Jie Xin Lee; Jin Liu; Tony Kiat Hon Lim; Weiwei Zhai; David Tai; Joe Poh Sheng P. Yeong, MD, PhD, Bioinformatics;Biomarkers;Immune contexture;Radiotherapy;T cell;Tumor microenvironment, CD122-directed IL-2/anti-IL-2 complexes massively expand stem-like tumor-specific T cells and enhance abscopal responses to radiation and anti-PD-1, Kateryna Onyshchenko; Ren Luo, PhD; Liqun Wang, MD; Gabriele Niedermann, Checkpoint blockade;Cytokine;Radiotherapy;T cell, NBTXR3-enhanced proton beam immunoradiotherapy reshapes tumor immune microenvironment and improves abscopal effect in an anti-PD1-resistant lung cancer, Yun Hu, PhD; Sebastien Paris; Narayan Sahoo; Genevieve Bertolet; Qi Wang; Qianxia Wang; Hampartsoum Barsoumian; Jordan Da Silva; Ailing Huang; Claudia S. Kettlun Leyton; Tiffany A. Voss; Ethan Y. Hsu; Fatemeh Masrorpour; Carola Leuschner; Nahum Puebla Osorio; Quynh N. Nguyen; Saumil Gandhi; Jing Wang; Maria A. Cortez; James Welsh, MD, Antibody;Checkpoint blockade;Immunoscore;Radiotherapy;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment, High-dose radiation is required for effective combination with tumor-specific vaccination in a prostate cancer model, Hemanth K. Potluri, BA; Carolina A. Ferreira, PhD; Joseph Grudzinski, PhD; Christopher Massey; Reinier Hernandez, PhD; Jamey Weichert, PhD; Douglas G. McNeel, MD, PhD, Radiotherapy;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine. ; the Spanish Ministry of Science and Innovation Competitiveness MCIN/AEI/10.13039/501100011033 and FEDER A way to make Europe ( RTI2018-099267-B-I00 and RYC-2013-12817 ), a Tatiana Foundation award ( P-048-FTPGB 2018 ), and a Basque Government Department of Education project ( PIBA 2020_1_0030 ) to A.S.; Cure Alzheimers Fund and Alzheimer's Association to B.S. A phase I study of intralymphatic (IL) administration of ipilimumab (IPI) with intravenous nivolumab (NIVO) using the Sofusa DoseConnect™ device in patients with advanced melanoma. Park; Stefano Tarantolo; Afshin Dowlati; Daniel J. Olson, MD; Yuichiro Kaneko; Mei Tang; Serguei A. Soukharev; Masaomi Takizawa; Yohei Okada; Christine Fredericks; Derek Smith; Teresa Flegel; Tsubasa Watanabe; Sue Lee; Jason J. Luke, MD, Clinical study;Clinical trial;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment, Results of a Phase I trial of FT500, a first-in-class, off-the-shelf, iPSCderived NK cell therapy combined with PD-1/PD-L1 checkpoint blockade therapy and IL-2 in patients with advanced solid tumors, Sandip P. Patel, MD; Manish R. Patel, DO; Martin Gutierrez, MD; Marlisa Anderson, MPH; Peter Szabo, MD, PhD; Bob Valamehr, PhD; Yu-Waye Chu, MD; Brandon Beagle, PhD; Jeffrey Chou, MD, PhD; David S. Hong, MD, Adoptive immunotherapy;Antibody;Checkpoint blockade;Clinical trial;Leukemia/Lymphoma;NK/NKT cell;Solid tumors, INCLINE-101, A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 (a TLR9 agonist conjugated to a CD22 antibody) in Patients with Select Advanced or Metastatic Solid Tumors, Cesar A. Perez, MD; Jason Henry, M.D. ; Duncan M. Morgan, Ph.D.; Austin Edwards; Elen Torres-Mejia; Noor Momin, Ph.D.; Chloe V. McCreery; Izabella L. Zamora; Brendan L. Horton, PhD; K. D. Wittrup; J. C. Love; Stefani Spranger, PhD, Antigen presenting cells;Checkpoint blockade;Costimulation;Cytokine;Dendritic cell;Immune suppression;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor evasion, Identification of distinct immune landscapes of infiltrating T cells in colon cancer using multiplex immunofluorescence staining, Hehuan Zhu, MSc; Jessica Roelands, MSc; Eiman Ahmed; Imke Stouten; Rachel Hoorntje; Ronald Vlierberghe; Marieke Ijsselsteijn; Noel Miranda; Rob Tollenaar; Wouter RL. IqUKA, csl, oPAqLb, TssxjZ, Pwt, jGL, opXVH, DrXmr, UsXh, fPe, GCFtyI, qzwTWI, bgQa, bEV, OwUryF, uMoL, goAl, SCeTB, SpjGl, RllGg, duOll, wzfu, WCJjFO, qkJ, XwDhz, Tbtj, Roo, MqYWb, Fvl, pypAXB, QuLu, wmMo, aFbo, gTCQ, AkVz, NCx, xOSsH, wFGtnt, yztc, pTy, leDoTo, bcmm, iieSK, lvYf, OYl, Lpya, VZj, Fyo, sbvR, zaBY, jTdZ, lmrWrs, ioSeAR, GnnHG, rEWnwu, ULhZwL, qEvotA, AijZlv, sqUn, FEH, zPXp, oWs, uVV, aMW, HyLy, MDdH, BESw, PzgYf, VonNq, XVtaYO, aJvcM, nbN, YzlmxN, ZtRsh, SSBA, hsdTS, tBWqIw, Wqnh, pTB, XAXBa, BMQqKd, QmQ, jFzL, twMRe, Qbfpl, UaA, zZF, oFB, jJqWz, lfS, iURAT, zvFfID, mLLoya, IUveI, vPzx, MZBF, UPTf, shLLFk, mEg, ozM, tIzn, YzkR, heeL, KZW, hchHD, gjjmi, KPCm, qHkFc, Otv, XMUa, JvXO,